Biopharmaceutical company Incyte (Nasdaq: INCY) has reported encouraging results from its Phase 3 STOP-HS clinical trials evaluating povorcitinib, an oral JAK1 inhibitor, for moderate to severe ...

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...

The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

Incyte Corporation (NASDAQ:INCY) released topline results from its pivotal Phase 3 STOP-HS clinical trial program of ...

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients with Hidradenitis ...

Christopher J. Sayed, MD, reports on how the 2025 American Academy of Dermatology Annual Meeting was an exciting event for hidradenitis suppurativa (HS), with increasing buzz and interest in the ...

HC Wainwright reissued their buy rating on shares of InflaRx (NASDAQ:IFRX – Free Report) in a report issued on Friday morning ...

Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.

A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte ( INCY 2.28%) stock over the past few days. The gloom this produced was pushing the biotech's ...

Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase ...